Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Litorina V and the Bergfalk group
Mandate

Vinge has advised Litorina V and the Bergfalk group

June 15, 2018 Banking and Finance

Vinge has advised Litorina V and the Bergfalk group in connection with the acquisition of Johan i Hallen i Göteborg AB, a leading Swedish distributor within fresh food with focus on meat.

The company has a turnover of over SEK 640 million and offers its products in Sweden. The company's former main owners and management will remain as significant owners going forward. Through the transaction a partnership is established between the Bergfalk-group and Johan i Hallen creating one of the leading specialist distributors within fresh food with focus on meat, fish and shellfish.

Vinge’s team consisted of partner Jonas Johansson together with the associates Carl Sander and Martin Cronsioe (M&A), Sara Strandberg and Sophia Holm (employment), Kristoffer Larson (real estate), Arvid Axelryd (IP) and Johan Cederblad (environment. Johan Wahlbom provided competition law advice. Partner Louise Brorsson Salomon and associate Sebastian Frisk assisted with the financing.
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025